Percutaneous Radiofrequency Ablation Versus Repeat Hepatectomy for Recurrent Hepatocellular Carcinoma
Hepatocellular carcinoma (HCC) is the fifth most common cancer in the world. Partial
hepatectomy is still considered as the conventional therapy for HCC. Intrahepatic recurrence
of HCC after partial hepatectomy is common and was reported to be more than 77% within 5
years after surgery. Repeat hepatectomy is an effective treatment for intrahepaticHCC
recurrence, with a 5-year survival rate of 19.4-56%. This is comparable to the survival
after initial hepatectomy for HCC. Unfortunately, repeat hepatectomy could be carried out
only in a small proportion of patients with HCC recurrence (10.4-31%), either because of the
poor functional liver reserve or because of widespread intrahepatic recurrence. In the past
two decades, percutaneous radiofrequency ablation (PRFA) has emerged as a new treatment
modality and has attracted great interest because of its effectiveness and safety for small
HCC (≤ 5.0 cm). Studies using PRFA to treat recurrent HCC after partial hepatectomy reported
a 3-year survival rate of 62-68%, which is comparable to those achieved by surgery. PRFA is
particularly suitable to treat recurrent HCC after partial hepatectomy because these tumors
are usually detected when they are small and PRFA causes the least deterioration of liver
function in the patients. To the best of our knowledge, there has been no report published
in the medical literature comparing the efficacy of repeat hepatectomy with PRFA for
recurrent HCC. The aim of this retrospective study is to compare the outcome of repeat
hepatectomy with PRFA for small recurrent HCC after partial hepatectomy.
Interventional
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment
overall survival
5-year
No
China: Ministry of Health
HCC16
NCT01570166
November 2011
June 2015
Name | Location |
---|